* Says phase iii tailor landmark study demonstrates
significant benefits of erbitux in combination with FOLFOX over
FOLFOX alone
The post BRIEF-Merck’s phase iii tailor landmark study demonstrates significant benefits of Erbitux in combination with FOLFOX over FOLFOX alone appeared first on NASDAQ.